An interventional study of Keeogo and adviced home practice in Multiple Sclerosis, sponsored by Pôle Saint Hélier. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Pôle Saint Hélier · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 376 studies in Multiple Sclerosis with a site in France — 63 open to participants now, 92 under way, 18 of them phase 3. Multiple Sclerosis · France.
Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 222nd largest by enrollment of the 244 interventional ones that give a count, is one of 14 that started in 2024, is one of 110 with no phase, and was the 321st registered.
3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →63 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:
University Hospital, Lille · Sites in France
Ages 18–65
University Hospital, Montpellier · Sites in France
Ages 40+
University Hospital, Caen · Sites in France
Ages 18+
Otto Bock France SNC · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
376 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 28 · Phase 3 77 · Phase 4 25
First in 1999; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 50 across 2,208 interventional studies indexed under Multiple Sclerosis.
Median enrollment 144 across the 244 interventional studies, 174 across the 132 observational. Of the 255 that completed or were terminated, 69 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 376 have an industry lead sponsor. The 10 most frequent:
Pôle Saint Hélier is the lead sponsor of 23 studies on the registry; 4 are open to participants now.
Pôle Saint Hélier has 4 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Multiple Sclerosis with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT03653273Phase 3Rennes University HospitalDisease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP) | 2027-07 |
| NCT05519553Nantes University HospitalPeer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis | 2026-12-01 |
| NCT07108088ÖSSUR FranceEvaluation of the NEUROSWING Orthosis on Walking Speed in a Population With Dorsal and/or Plantar Flexor Deficits, With a View to a Reimbursement Application | 2026-12-31 |
| NCT05772637Assistance Publique - Hôpitaux de ParisClinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis | 2027-02-14 |
Add all 18 to your calendar (.ics) → With an account.
Among the 376 studies in Multiple Sclerosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical investigation is to evaluate the effectiveness of home use of a lightweight robotic lower limb exoskeleton as a walking aid device on quality of life in patients with multiple sclerosis with gait disorders.
Participants will wear an exoskeleton (Keeogo) for 8 weeks at home during the experimental phase. This phase is compared to an 8-week control phase at home with advice on regular physical activity adapted to their abilities.
It is a multicenter, controlled, randomized, cross-over, open-label clinical investigation.
Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) between 5 and 6.5,living at home and using an assistive device for walking will be included.
After enrollment, patients will be randomised in one of the 2 study-arm.
During the experimental phase, patients will receive a Keeogo specific training for five days. The purpose of this training programme is to ensure familiarity and acceptance of the device. Then, the patients will take Keeogo home and will have to use the device as much as possible indoors and outdoors for seven weeks.
During the control phase, patients will be at home for eight weeks with advice on regular physical activity adapted to their abilities.
After the second phase, all patients will have a 3 months of follow-up.
Inclusion Criteria:
Non-Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
8 weeks of using keeogo at home (experimental phase) followed by 8 weeks of wash-up and then followed by 8 weeks of recommended home practise (control phase).
Device: Keeogo · Other: adviced home practice
8 weeks of recommended home practise (control phase) followed by 8 weeks of wash-up and then followed by 8 weeks of using keeogo at home (experimental phase)
Device: Keeogo · Other: adviced home practice
Keeogo is exoskeleton for walking assistance
health tips for regular and appropriate physical activity
Evolution of the quality of life assessed with the "Functional Assessment Of Multiple Sclerosis" questionnaire (change between two time points)
The Functional Assessment Of Multiple Sclerosis (FAMS) is a self-administered health questionnaire related to quality of life for patients with multiple sclerosis
Time frame: Screening visit and visit after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance with the Keeogo exoskeleton (1)
Measured by 2 minutes walking test
Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance with the Keeogo exoskeleton (2)
Measured by 10 meter walking test
Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance with the Keeogo exoskeleton (3)
Measured by the Timed up and go Test
Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance with the Keeogo exoskeleton (4)
Measured by Functional Stair Test (FST)
Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance with the Keeogo exoskeleton (5)
Measured by the Sit to Stand Test (SST)
Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance with the Keeogo exoskeleton (6)
Evaluations of spatio-temporal gait parameters using an instrumented walking system (Gaitrite®, Vicon® or Locometer® for example)
Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Spasticity of the quadriceps, hamstrings and abductors muscles
Assessed manually by the Held and Tardieu Test
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Sense of self-efficacy
Measured by the Rosenberg Self-Efficacy Questionnaire
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
The average daily distance travelled
Measured by inertial units tracing the daily activity of the participants (descriptive daily distance travelled)
Time frame: At study visits (Week 8, Week 24, Month 9)
Fatigue
Measured by the French version of the fatigue impact scale in multiple sclerosis (EMIF-SEP) scored from 0 to 100% a low score is a better outcome
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Anxiety and depression
Measured by the Hospital Anxiety and Depression score (HAD) scored from 0 to 21 for both subtitles (Anxiety and depression) a low score is a better outcome
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Satisfaction with this new home technical aid
Evaluated via the French version of the QUEST questionnaire (ESAT questionnaire)
Time frame: After experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Projection in use
Evaluated by a usage questionnaire (UTAUT-based already used in a walking exoskeleton context)
Time frame: After experimental phase (Week 8 for Arm A; Week 24 for Arm B)
Walking and balancing performance without exoskeleton (1)
Measured by the 2 minutes walking test
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Walking and balancing performance without exoskeleton (2)
Measured by the 10 meter walking test
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Walking and balancing performance without exoskeleton (3)
Measured by the Timed up and go Test
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Walking and balancing performance without exoskeleton (4)
Measured by the Functional Stair Test (FST)
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Walking and balancing performance without exoskeleton (5)
Measured by the Sit to Stand Test (SST)
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Walking and balancing performance without exoskeleton (6)
Evaluations of spatio-temporal gait parameters using an instrumented walking system (Gaitrite®, Vicon® or Locometer® for example)
Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)
Plan to share: No
Ran from Feb 2024 to primary completion in Sep 2026, 31 months.
Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 31 months is above that.
Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pôle Saint Hélier